



Universiteit
Leiden
The Netherlands

Discovery of novel antibiotics from actinomycetes by integrated metabolomics & genomics approaches

Wu, Changsheng

Citation

Wu, C. (2016, October 26). *Discovery of novel antibiotics from actinomycetes by integrated metabolomics & genomics approaches*. Retrieved from <https://hdl.handle.net/1887/43768>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/43768>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/43768> holds various files of this Leiden University dissertation

Author: Wu, Shangsheng

Title: Discovery of novel antibiotics from actinomycetes by integrated metabolomics & genomics approaches

Issue Date: 2016-10-26

Chapter 7

The cryptic *qin* gene cluster of *Streptomyces* sp. MBT76 specifies C-glycosylpyranonaphthoquinones with new chemistry

Changsheng Wu ^{1,2}, Chao Du ¹, Koji Ichinose ³, Young Hae Choi ², and Gilles P. van Wezel ¹

¹ *Molecular Biotechnology, Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, The Netherlands*

² *Natural Products Laboratory, Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, The Netherlands*

³ *Research Institute of Pharmaceutical Sciences, Musashino University, Shinmachi, Nishitokyo-shi, Tokyo 202-8585, Japan*

Submitted for publication

ABSTRACT

Antimicrobial resistance is one of the major threats to human health care. Mining of microbial genomes has revealed that actinomycetes harbor far more biosynthetic potential than anticipated. The activation of (cryptic) biosynthetic gene clusters and subsequent identification of the corresponding metabolites is a major strategy in modern drug discovery approaches. Here, we elucidated the structure of and the biosynthetic pathway for novel *C*-glycosylpyranonaphthoquinones in *Streptomyces* sp. MBT76, via an integrated genomics and metabolomics approach. Following activation of the cryptic *qin* gene cluster for a type II PKS by constitutive expression of its pathway-specific activator, bioinformatics coupled to NMR profiling facilitated the chromatographic isolation and structural elucidation of qinimycins A—C (**1—3**). The intriguing structural features of the qinimycins, including 8-*C*-glycosylation, 5,14-epoxidation and 13-hydroxylation, distinguished these molecules from the model pyranonaphthoquinones actinorhodin, medermycin, and granaticin. Another novelty lies in the unusual fusion of a deoxyaminosugar to the pyranonaphthoquinone backbone during biosynthesis of the antibiotics BE-54238 A and B (**4, 5**). Qinimycins showed antimicrobial activity against Gram-positive but not against Gram-negative bacteria. Our work shows the utility of combining bioinformatics, targeted activation of cryptic gene clusters and NMR-based metabolic profiling as a pipeline to discover microbial natural products with distinctive skeletons.

1. INTRODUCTION

Actinomycetes are prolific sources of bioactive natural products (NPs). From the roughly 18,000 known bioactive bacterial compounds, more than 10,000 were discovered from the actinomycete genus *Streptomyces*.^{1,2} Even so, their biosynthetic potential is far from exhausted, though the enthusiasm to discover new molecules produced by these bacteria is dampened by chemical redundancy and the consequential poor return of investment of high-throughput screening campaigns.^{3–5} On a more positive note, whole genome sequencing revealed that actinomycetes harbor numerous silent and hence likely untapped biosynthetic gene clusters (BGCs) that may not be associated with known metabolites; indeed, even the very extensively studied model organism *Streptomyces coelicolor* was shown to possess a far greater producing potential than anticipated.⁶ Furthermore, bioinformatics tools developed specifically for mining genome sequences for the identification of BGCs allow the prediction of the chemical output of many BGCs on the basis of accumulated biosynthetic knowledge.^{7,8} These giant developments in genome mining mark the start of a new era of genomics-based drug discovery, with the potential of greatly expanding the chemical space of bioactive natural products.

A bottle-neck is that many of the biosynthetic pathways uncovered by genome sequencing are in a dormant state under routine laboratory conditions, generally referred to as cryptic or silent gene clusters, and specific approaches to activate their expression are required.^{9,10} The transcription of genes encoding the biosynthetic machinery for secondary metabolites in actinomycetes involves multiple regulatory cascades and networks.¹¹ The regulatory signals are transmitted through global regulatory networks and ultimately transmitted to the pathway-specific regulatory genes that control the expression of the biosynthetic genes.¹² Strategies to circumvent the regulatory networks that silence cryptic BGCs and trigger the biosynthesis of the corresponding natural product(s) include manipulating the pleiotropic regulatory networks as well as targeting pathway-specific regulators.^{10,13}

Another challenge is how to rapidly identify the relevant NPs within the context of the complex metabolic matrix. Metabolomic profiling is an efficient tool to achieve this goal. The available bioinformatic information allows prediction of the metabolite produced by the BGC, and this knowledge can be directly related to the ¹H NMR spectrum by examining the expected chemical shift and/or splitting pattern of typical protons in the predicted molecular motifs. In turn, as one compound usually contains multiple ¹H resonances, any unique NMR feature(s) in its structure can be used to check for the expression of the corresponding BGC and subsequently for NMR-guided chromatographic separation. This should allow scientists to bridge the gap between bioinformatics-driven gene cluster analysis and experimental NPs discovery.¹⁴

In this study, we activated the expression of a cryptic BGC identified in the genome of *Streptomyces* sp. MBT76, followed by NMR-based metabolomics to facilitate the characterization of the NPs. Constitutive expression of the likely pathway-specific activator of the type II PKS gene cluster (designated *qin*) activated the biosynthesis of a family of pyranonaphthoquinones with intriguing chemical architecture. Genomics and structural analysis identified a family of 8-*C*-glycosyl-pyranonaphthoquinones (**1–5**). The qinimycins A–C (**1–3**) encompass structural features of a rare 5,14-epoxidation and unprecedented

13-hydroxylation in pyranonaphthoquinones. In addition, an unusual fusion of a deoxyaminosugar into a pyranonaphthoquinone backbone was seen for the previously described antibiotics BE-54238A (4) and BE-54238B (5). Antimicrobial property of qinimycins was evaluated.

2. RESULTS AND DISCUSSION

2.1. Identification and activation of the cryptic type II PKS gene cluster (*qin*) for glycosylated pyranonaphthoquinones

Streptomyces sp. MBT76, which originates from the Qinling mountains in China, was previously identified as a prolific producer of antibiotics, including those with efficacy against multiple Gram-positive and Gram-negative MDR pathogens.¹⁵ Further detailed metabolic characterization of the strain identified many natural products with often interesting chemistry, including isocoumarins, prodiginines, acetyltryptamine, and fervenulin among others.¹⁶ *Streptomyces* sp. MBT76 was subjected to Illumina/Solexa whole genomic sequencing, and the genome was assembled in 13 contigs, with a total genome size of 8.64 Mb. In total 7974 coding sequences (CDS) were predicted using the GeneMark algorithm.¹⁷ Analysis of the contigs by AntiSMASH¹⁸ presented a possible 55 putative biosynthetic gene clusters (BGCs) specifying secondary metabolites, 22 of which encoding polyketide synthases (PKS).

One 41 kb biosynthetic gene cluster for a type II PKS, designated *qin* (Table 1) was of particular interest considering its potential to specify pyranonaphthoquinones, a well-studied family of aromatic polyketides with highly complex chemical architecture and pronounced bioactivities,^{19,20} including the representative members actinorhodin,²¹ medermycin,²² and granaticin.²³ In the *qin* BGC, besides the central PKS genes that are responsible for the biosynthesis of the pyranonaphthoquinone backbone, the presence of genes for the deoxyaminosugar D-forosamine in the upstream strongly suggested that the end product should be glycosylated. This genetic organization was similar to the clusters for synthesis of the glycosylated pyranonaphthoquinone medermycin in *Streptomyces* sp. AM-7161 (*med*)²² and granaticin in *Streptomyces violaceoruber* Tü22 (*gra*).²³ Coclustering of glycosylation-associated biosynthetic genes with those for the aglycones is typical of microbial genomes, which facilitates matching the BGC to the corresponding NPs.²⁴ In comparison, *qin*-ORF29 for an NADPH-dependent FMN reductase was absent in either the *med* or *gra* BGCs, and decoration with a D-forosamine is unprecedented in the pyranonaphthoquinone family. This promoted investigation into the potentially novel product(s) of the *qin* BGC. However, despite our previous detailed phytochemical investigations of *Streptomyces* sp. MBT76,^{15,16} the corresponding molecules had not been identified, suggesting that the gene cluster may be cryptic under the many different growth conditions that had been tested.

The *qin* BGC contains two putative regulatory genes, namely the SARP-family transcriptional regulatory gene *qin*-ORF11, and the TetR-family regulatory gene *qin*-ORF35 (Table 1). Many pathway-specific activators for secondary metabolite production in streptomycetes belong to the SARP family,¹² while TetR-family regulators often act as repressors.²⁵ As an example, in the type II PKS gene cluster *aur1* of *Streptomyces aureofaciens* CCM 3239, which specifies the angucycline-family auricin²⁶, *aur1P* and

aur1PR3 encode SARP-family activators,²⁷ while the *tetR*-type *aur1R* encodes a negative regulator.²⁸ To activate the *qin* gene cluster, we opted to over-express the likely pathway-specific activator gene *qin*-ORF11. For this, the gene was amplified by PCR and inserted behind the *ermE** promoter²⁹ in the conjugative and integrative vector pSET152. The resulting plasmid was then integrated into the *attB* site of the chromosome of MBT76 to create the recombinant derivative MBT76-1.

Table 1. Predicted functions of the gene products of the qinimycins biosynthetic gene cluster (*qin*) of *Streptomyces* sp. MBT76.

CDS	Length	Putative function	Nearest orthologue found in	aa identity	Accession number
1	322	dTDP-glucose 4,6-dehydratase	<i>Streptomyces</i> sp. NRRL S-623	79%	WP_031121809.1
2	359	dTDP-1-glucose synthase	<i>Streptomyces vietnamensis</i>	69%	ADO32770.1
3	280	<i>N</i> -methyltransferase	<i>Streptomyces clavuligerus</i>	39%	WP_003953258.1
4	365	<i>C</i> -glycosyltransferase	<i>Streptomyces</i> sp. SCC 2136	48%	CAF31363.2
5	385	NDP-hexose aminotransferase	<i>Streptomyces ambofaciens</i>	72%	CAM96587.1
6	421	Hypothetical protein	<i>Streptomyces violaceoruber</i>	45%	CAA09645.1
7	436	NDP-hexose 2,3-dehydratase	<i>Streptomyces</i> sp. NRRL S-623	67%	WP_031121795.1
8	351	NDP-hexose 3-ketoreductase	<i>Streptomyces</i> sp. NRRL S-623	64%	WP_032774990.1
9	432	NDP-hexose-3,4-dehydratase	<i>Streptomyces lydicus</i>	79%	CBA11561.1
10	378	flavin-dependent monooxygenase	<i>Streptomyces</i> sp. AM-7161	59%	BAC79043.1
11	267	SARP family transcriptional regulator	<i>Streptomyces cyaneofuscatus</i>	70%	WP_030562180.1
12	312	polyketide cyclase	<i>Streptomyces aureofaciens</i>	73%	YP_009060633.1
13	287	4-phosphopantetheinyl transferase	<i>Streptomyces albus</i>	45%	WP_031175178.1
14	571	type I polyketide synthase component	<i>Streptomyces scabiei</i>	44%	YP_003491848.1
15	142	hydroxylacyl-CoA dehydrogenase	<i>Streptomyces</i> sp. NRRL F-5135	69%	WP_030744938.1
16	334	bifunctional cyclase/dehydratase	<i>Streptomyces lavenduligriseus</i>	70%	WP_030792829.1
17	87	acyl carrier protein	<i>Streptomyces</i> sp. R1128	69%	AAG30201.1
18	410	Chain-Length Factor (polyketide beta-ketoacyl synthase beta subunit)	<i>Streptomyces lividans</i>	73%	WP_003973890.1
19	418	actinorhodin polyketide beta-ketoacyl synthase alpha subunit	<i>Streptomyces lavenduligriseus</i>	85%	WP_030792818.1
20	420	putative transporter	<i>Streptomyces viridochromogenes</i>	50%	WP_003988487.1
21	166	flavin reductase	<i>Streptomyces fulvoviolaceus</i>	57%	WP_052425229.1
22	261	ketoacyl reductase	<i>Streptomyces chartreusis</i>	72%	WP_01003439
23	309	hydroxylacyl-CoA dehydrogenase	<i>Streptomyces</i> sp. NRRL S-31	67%	WP_030735501.1
24	303	Quinone oxidoreductase	<i>Nocardia</i> sp. CNY236	72%	WP_028476080.1
25	217	DSBA-type oxidoreductase	<i>Streptosporangium roseum</i>	63%	WP_012891327.1
26	191	dehydratase	<i>Streptomyces</i> sp. AM-7161	55%	BAC79041.1
27	576	stereospecific keto reductase	<i>Streptomyces</i> sp. AM-7161	64%	BAC79036.1
28	328	Quinone oxidoreductase	<i>Streptomyces</i> sp. AM-7161	71%	BAC79039.1
29	201	NADPH-dependent FMN reductase	<i>Streptomyces</i> sp. NRRL S-623	64%	WP_031121793.1
30	402	<i>S</i> -adenosylmethionine synthetase	<i>Streptomyces roseoverticillatus</i>	95%	WP_030365339.1
31	339	adenosine kinase	<i>Streptomyces albulus</i>	72%	AIA08031.1
32	1167	methionine synthase	<i>Streptomyces roseoverticillatus</i>	93%	WP_030367617.1
33	312	5,10-methylenetetrahydrofolate reductase	<i>Streptomyces</i> sp. NRRL F-5135	81%	WP_030742694.1
34	473	adenosylhomocysteinase	<i>Streptomyces roseoverticillatus</i>	90%	WP_030365247.1
35	227	TetR family transcriptional regulator	<i>Streptomyces lividans</i>	49%	WP_003972639.1

2.2. NMR-based metabolic profiling expedited characterization of novel glycosylated pyranonaphthoquinones

Ex-conjugant MBT76-1 and its parent MBT76 were fermented in parallel in liquid modified

NMMP media.¹⁶ After five days of growth, the cultures were harvested by centrifugation and extracted with EtOAc. The obtained metabolites were subjected to ¹H NMR profiling.³⁰ As shown in Figure 1, MBT76-1 presented a very different metabolic profile in comparison to the parental strain. The production of many of the metabolites usually produced by the wild-type strain, such as 1*H*-pyrrole-2-carboxamide, acetyltryptamine, fervenulin and 2-hydroxy-3-methoxy-benzamide,¹⁶ was aborted in MBT76-1. While the production of 6,8-dihydroxy-3-methyl-isocoumarin (**9**) was not affected by ORF11 overexpression, its post-PKS methoxylation was hampered as shown by the disappearance of methoxyl groups in the region δ 3.45—4.25.¹⁶ Conversely, the ¹H NMR spectra of MBT76-1 now exhibited many previously unseen proton resonances absent in the parental strain, indicating that different compounds were produced. These included molecules with characteristic NMR signals such as δ 4.45 (dd, $J = 4.2, 1.8$ Hz) for the methine in a substituted pyran ring, and the methyl doublet at δ 1.29 (d, $J = 6.6$ Hz) which were in agreement with kalafungin (16-CH₃) or 6'-deoxy-CH₃ of a sugar moiety predicted by bioinformatics; In the aromatic region, coupling doublets at δ 8.01 (d, $J = 8.4$ Hz), and 6.56 (d, $J = 8.4$ Hz) were indicative of an α,β -unsaturated ketone aryl moiety typical of pyranonaphthoquinones. All these NMR features indicated that indeed the *qin* gene cluster was actively expressed in MBT76-1.




Figure 1. Comparison of ¹H NMR spectra. ¹H NMR (600 MHz, in methanol-*d*₄) was obtained on the crude extracts from wild-type strain *Streptomyces* sp. MBT76 (bottom) and its ex-conjugant MBT76-1 (top). The presented chemical shifts are for aromatic region δ 6.5—8.1 and aliphatic region δ 1.2—4.5. The signals highlighted by arrows are attributable to glycosylated pyranonaphthoquinone molecules.

To identify the metabolic product(s) of the *qin* gene cluster, the molecules were separated chromatographically by semi-preparative HPLC-UV chromatography. The resulting fractions (Fr1—16) were analysed by ¹H NMR spectroscopy, which showed that Fr1 (2.1 mg) contained the sought-after deoxysugar-pyranonaphthoquinones. Further UHPLC-UV-ToF-HRMS analysis confirmed Fr1 mainly contained three structurally related compounds, with molecular formulas C₂₃H₂₇NO₈ (**1**), C₂₃H₂₉NO₉ (**2**), and C₂₄H₃₁NO₉ (**3**) with a relative abundance of 6:2:1 (Figure S1). Elucidation of the final structure of major compound **1** was done on the basis of extensive NMR analysis, including ¹H NMR, HSQC, HMBC, COSY, and APT. The ¹H NMR spectrum of compound **1** (Table 2) presented characteristic resonances for the bioinformatics-predicted deoxyaminosugar forosamine, including a 6'-deoxy-CH₃ doublet at δ_{H} 1.29 (d, $J = 6.6$ Hz), a 7'-*N*-CH₃ singlet at δ_{H} 2.89 (s), and highly overlapping signals for 2',3'-deoxy-CH₂ at δ_{H} 2.20~2.40. Aided by COSY and HSQC experiments (Figure S2), the backbone of the aglycone was confirmed as a

kalafungin-type molecule, as established by the spin system H₂-2/H-3/H-4 for a γ -lactone ring, together with two coupling protons at δ_{H} 1.41 (d, $J = 6.6$ Hz, H-16) and 4.93 (q, $J = 6.6$ Hz, H-15) for a pyran ring. The additional two aromatic coupling doublets δ_{H} 7.65 (d, $J = 8.4$ Hz, H-9), and 7.25 (d, $J = 8.4$ Hz, H-10) indicated that the deoxyaminosugar was linked to the aglycone through the C-8 residue of the benzene ring, which was confirmed by the HMBC correlations (Figure S2) from H₂-2' (δ_{H} 2.30, 2.24) to C-8 (δ_{C} 124.2) and from H-9 (δ_{H} 7.65) to C-1' (δ_{C} 68.7). More importantly, the key HMBC correlations from the H-13 (δ_{H} 5.48) to C-11 (δ_{C} 158.1), C-12 (δ_{C} 129.2), C-7 (δ_{C} 131.1), C-5 (δ_{C} 60.6), C-14 (δ_{C} 68.1), and C-15 (δ_{C} 65.9) demonstrated that the pyranonaphthoquinone skeleton of kalafungin (**6**) acquired two variations, via the epoxidation of the $\Delta^{5,14}$ double bond and hydroxylation of the ketone at C-13. The stereochemistry at C-13 was established as *R*, based on the NOESY correlation between H-13/H₃-16, but no correlation was observed for H-13/H-15. However, the configuration of 5,14-epoxy remained unclear. Consequently, the final structure of major compound **1** (Figure 2) in Fr1 was elucidated as a novel glycosylated pyranonaphthoquinone, and named qinimycin A. Similar NMR spectral analyses revealed that compound **2** was a hydration product of **1** in the γ -lactone ring (Table 2), and accordingly named qinimycin B. Though compound **3** (qinimycin C) was not resolved by NMR spectra due to its low abundance, the additional mass of 14.0153 (Figure S1) corresponding exactly to a CH₂ unit suggested that the imide in **2** was further methylated into a tertiary amine, since the *N*-methyltransferase ORF3 is able to *di*-methylate the nitrogen atom of dTDP-D-forsamine in spinosyn pathway.³¹ The known compounds **4**—**14** (Figure 2) were identified in Fr2—Fr16 by ¹H NMR and/or UHPLC-UV-ToF-HRMS, and the results were compared with spectroscopic data from the literature (Table S1).

Table 2. ¹H and ¹³C NMR data for compounds **1** and **2**^a

NO.	1		2	
	δ_{C} , type	δ_{H} (J in Hz)	δ_{C} , type	δ_{H} (J in Hz)
1	177.4, C		174.4, C	
2	37.3, CH ₂	2.91, dd (15.6, 4.2); 2.40, dd (15.6, 1.8)	36.5, CH ₂	2.58, d (7.2)
3	68.0, CH	4.45, dd (4.2, 1.8)	67.1, CH	4.16, m
4	74.0, CH	4.98, d (1.2)	64.0, CH	4.32, d (12.6)
5	60.6, C		63.0, C	
6	194.6, C		197.1, C	
7	131.1, C		131.5, C	
8	124.2, C		124.1, C	
9	132.2, CH	7.65, d (8.4)	132.1, CH	7.62, d (8.4)
10	121.4, CH	7.25, d (8.4)	121.3, CH	7.23, d (8.4)
11	158.1, C		158.1, C	
12	129.2, C		129.3, C	
13	61.0, CH	5.48, d (0.6)	61.2, CH	5.43, d (0.6)
14	68.1, C		67.7, C	
15	65.9, CH	4.93, q (6.6)	65.7, CH	4.90, q (6.6)
16	14.1, CH ₃	1.41, d (6.6)	14.4, CH ₃	1.40, d (6.6)
1'	68.7, CH	5.36, m	68.7, CH	5.36, m
2'	32.1, CH ₂	2.30, m; 2.24, m	32.1, CH ₂	2.30, m; 2.24, m
3'	22.5, CH ₂	2.38, m; 2.21, m	22.5, CH ₂	2.38, m; 2.21, m
4'	75.0, CH	3.63, td (7.2, 1.8)	75.0, CH	3.63, td (7.2, 1.8)
5'	63.8, CH	4.27, m	63.8, CH	4.27, m
6'	19.9, CH ₃	1.29, d (6.6)	19.9, CH ₃	1.29, d (6.6)
7'	39.0, CH ₃	2.89, s	39.0, CH ₃	2.89, s

^a **1** and **2** were recorded in CD₃OD. Proton coupling constants (J) in Hz are given in parentheses. All chemical shift assignments were done on the basis of 1D and 2D NMR techniques.




Figure 2. Secondary metabolites produced by *Streptomyces* sp. MBT76-1. Compounds identification was done on the basis of NMR and HRMS techniques, and their spectroscopy data were summarized in Table 2 and Table S1.

The qinimycins have intriguing chemical features, representing a new branch within the extensively studied pyranonaphthoquinone family of natural products. The 5,14-epoxidation was previously described in pyranonaphthoquinone aglycones,^{32,33} but hydroxylation of the pyranonaphthoquinone backbone at C-13 is unprecedented. The 8-C-glycosylation of pyranonaphthoquinone is rare, though previously seen in the antibiotic Sch 38519,^{34,35} and xiakemycin A.³⁶ Within the pyranonaphthoquinones, glycosylation with the deoxyaminosugar forosamine is uniquely seen in the qinimycins. With this chemical architectural complexity, the qinimycins rival the well-known pyranonaphthoquinone glycosides medermycin²² or granaticin²³ in terms of structural complexity. The antimicrobial activity of qinimycins were evaluated by agar diffusion assays. Growth inhibition was seen for the Gram-positive bacteria *Bacillus subtilis* 168 and *Staphylococcus aureus* CECT976, but not for Gram-negative *Escherichia coli* JM109 or *Pseudomonas aeruginosa* PAO1 (Table 3).

Table 3. Antimicrobial activity of qinimycins.

Compound NO.	Inhibition zone (mm)			
	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>	<i>Staphylococcus aureus</i>	<i>Pseudomonas aeruginosa</i>
Fr1	15	0	20	0
AMP	23	20	10	7
APRA	10	7	7	15
NC	0	0	0	0


For Fr1, 25 μ L was spotted of a 2 mg/mL solution in methanol; For AMP and APRA, 5 μ L was spotted of a 1 mg/mL solution in miliQ water. AMP, ampicillin; APRA, apramycin; NC, negative control (methanol).

2.3. Proposed biosynthetic pathway for qinimycins based on bioinformatics analysis

A biosynthetic model for qinimycins is proposed based on the functional assignments from sequence analysis and the known metabolites that are produced (Figure 3). The assembly line includes three steps: (i) biosynthesis of an activated form of dTDP-D-forosamine, similar to that found in the spinosyn pathway;³¹ (ii) assembly of the kalafungin aglycone by a minimal PKS similar to that found in the BGCs for medermycin²² and granaticin;²³ and (iii) regioselective installing of a dTDP-D-forosamine moiety at the C-8 position of kalafungin by a C-glycosyltransferase (most likely encoded by *qin*-ORF4).

In a pilot study of actinorhodin biosynthesis, a two-component flavin-dependent monooxygenase (FMO), encoded by *actVA*-ORF5 (oxygenase) and *actVB* (flavin reductase), was demonstrated to perform the two consecutive oxygenations at C-6 and C-8.³⁷ The FMO genes are commonly present in the *med* and *gra* BGCs for medermycin²² and granaticin,²³ respectively. The ActVA homologue Gra-21 was shown to be bifunctional at C-6 and C-8, whereas Med-7 mono-functionally oxygenizes the C-6 position. Interestingly, the gene product of *qin*-ORF10 shows higher similarity to Med-7 (59% aa identity) than to ActVA-ORF5 (53% aa identity), suggesting possible mono-functionality at C-6. The single oxygenation at C-6 leading to a pyranonaphthoquinone skeleton is in good agreement with the subsequent C-glycosylation for qinimycins at C-8 and medermycin at C-10, where the selectivity of the responsible glycosyl transferase *qin*-ORF4 is of great interest. Further studies³³ on ActVA-ORF5/ActVB revealed its additional *in vitro* epoxidation activity of kalafungin. The co-occurrence of three qinimycins (**1**–**3**) is a clear example of *in vivo* activity of a two-component FMO encoded by *qin*-ORF10/*qin*-ORF21. Compared with the *act*,⁶ *med*,²² and *gra*²³ gene clusters, *qin*-ORF29 for an NADPH-dependent FMN reductase is unique in the *qin* BGC. We propose that this enzyme may execute the unprecedented reduction of the C-13 ketone.

It is noteworthy that, based on the biosynthetic pathway (Figure 3), we predict that also qinimycins other than compounds (**1**–**3**) are produced by *Streptomyces* sp. MBT76, which may have been missed due to lower yields. For instance, UHPLC-UV-ToF-HRMS analysis of MBT76-1 crude extract showed molecules with the molecular formulae C₂₃H₂₇NO₉ and C₂₃H₂₅NO₈ for the putative compounds **1a** and **1b**, respectively. The post-PKS glycosylation of 8-C-glycosylpyranonaphthoquinones BE-54238A (**4**) and BE-54238B (**5**)³⁸ involved rearrangement of the deoxyaminosugar moiety. After glycosylation of kalafungin into **5a**, the six-membered amino pyran ring was first rearranged into a five-membered 2*H*-3,4-dihydropyrrole ring through a *Mannich* reaction, whereby the gene product of *qin*-ORF6 might mediate the ring-opening of the appended forosamine to a linear ketone. The newly formed imide was then further cyclized with the aglycone quinone at C-6 to give an intermediary iminium ion, which subsequently underwent proton tautomerization to produce antibiotic BE-54238A/B. Interestingly, this naturally occurring biosynthetic pathway mimics the total synthesis of BE-54238B from rhamnose.^{39,40} The anthraquinones 11-*O*-methyl-aloesaponarin II (**8**) and 3,8-dihydroxy-1-methyl-anthraquinone-carboxylic acid (**9**) were shunt products of the kalafungin biosynthetic pathway,⁴¹ but it remains unclear whether polyketide molecules **10**–**12** were also derived from the *qin* BGC.



3. CONCLUSION

The replication issues that have frustrated high-throughput screening regimes necessitate new approaches to expand the chemical diversity of natural products and keep filling the discovery pipelines with new lead compounds. The combination of metabolomics and genome mining is an efficient way to streamline the discovery of novel molecules from actinomycetes. Prior knowledge of the types of NPs that can be expected based on bioinformatics thereby simplifies the phytochemical isolation process and final structure determination of target compound(s), while NMR profiling of molecules in highly complex matrices allows rapid linkage of chemotype to genotype. We here provide proof of concept for this principle, whereby activation of the cryptic *qin* type II PKS gene cluster by constitutive expression of its pathway-specific activator gene (*qin*-ORF11) followed by NMR-based metabolic profiling, identified novel glycosylated pyranonaphthoquinones with exciting chemical architecture (1–5). The elucidated biosynthetic pathway for the qinimycins in the genetically tractable *Streptomyces* sp. MBT76 offers new insights into the biosynthesis of this exciting family of natural products. The best studied pyranonaphthoquinone is undoubtedly actinorhodin produced by *Streptomyces coelicolor* A3(2), which is the archetype of this family of polyketides. The qinimycins described in this work have intriguing structural features that make them stand out, namely 8-C-glycosylation by the deoxyaminosugar D-forosamine, as well as 5,14-epoxidation and 13-hydroxylation. Another novelty lies in the unusual fusion of the deoxyaminosugar to the pyranonaphthoquinone backbone during biosynthesis of the antibiotics BE-54238 A and B. Thus, the qinimycins form a new branch of the family of pyranonaphthoquinone-type antibiotics and provides important new insights into the biosynthesis of this important class of natural products.

4. EXPERIMENTAL SECTION

4.1. Bacterial strains and culturing conditions

Streptomyces sp. MBT76 was obtained from the culture collection of Molecular Biotechnology, IBL, Leiden University. *Escherichia coli* JM109⁴² was used for routine cloning. *Escherichia coli* ET12567⁴³ containing pUZ8002⁴⁴ was used for introducing non-methylated DNA into *Streptomyces* by conjugation. The basal medium for *Streptomyces* sp. MBT76 growth was modified minimal liquid medium NMMP⁴⁴ without PEG6000 and containing 1% (w/v) glycerol and 0.5% (w/v) mannitol as the carbon sources, which was further supplemented with 0.8% (w/v) Bacto peptone.¹⁶ Tryptone soy broth with 10% sucrose (TSBS) was used to grow MBT76 mycelia as receptor for conjugation experiments. Soy flour mannitol (SFM) agar plates⁴⁴ were used to grow overexpression conjugants of MBT76. For culturing of MBT76 for chemical analysis, 50 mL modified NMMP was inoculated with 10⁶ spores of *Streptomyces* sp. MBT76 in 250 mL flasks equipped with a spring, and grown at 30 °C with constant shaking at 220 rpm. The incubation lasted for 120 h.

4.2. Genome sequencing, assembly, and annotation

DNA was extracted from *Streptomyces* sp. MBT76 as described.⁴⁴ Genome sequencing and annotation was done essentially as described previously.⁴⁵ Illumina/Solexa sequencing on Genome Analyzer Iix and sequencing on PacBio RS were outsourced to BaseClear BV

(Leiden, The Netherlands). 100-nt paired-end reads were obtained and the quality of the short reads verified using FastQC (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/>). Depending on quality, reads were trimmed to various lengths at both ends. Processed raw reads were subsequently used as input for the Velvet assembly algorithm. Genomes were annotated using the RAST server with default options. Contigs were also annotated using GeneMark.hmm¹⁷ for ORF prediction, BLASTP for putative function prediction and HMMER for protein-domain prediction, manually inspected for some and visualized using Artemis. The genome has been deposited at GenBank under the accession LNBE00000000.

4.3. Overexpression of the pathway-specific SARP regulator *qin*-ORF11

qin-ORF11 was amplified by PCR from *Streptomyces* sp. MBT76 genomic DNA as described⁴⁶ using primers SC06_0044_F_EcoRI 5'-CGATGAATTCGTCGCGCTTCGTGTG and SC06_0044_R_EcoRI_NdeI

5'-CGATGAATTCGCACCCGGTACAGGAGTGTGTGTCATATGCGATTCAACCTCATC.

The PCR product was subcloned as an EcoRI fragment and subsequently ligated as an NdeI-HindIII fragment behind the constitutive *ermE* promoter in pSET152,²⁹ which integrates at the ϕ C31 attachment site in the *Streptomyces* chromosome. The final recombinant plasmid pCSW01 (pSET152/*ermE*/*qin*-ORF11) was subsequently transformed into *Escherichia coli* ET12567/pUZ8002 and the positive transformant was selected by 100 μ g/mL apramycin. This strain was then used to conjugate two-day old mycelia of *Streptomyces* sp. MBT76. The ex-conjugant was confirmed by PCR using primers SC06_0044_SF 5'-TTTCCCAGTCACGACGTTG and SC06_0044_SR 5'-GGATAACAATTCACACAGG.

4.4. Metabolomics and compound purification

50 mL cultures of *Streptomyces* sp. MBT76 or MBT76-1 were harvested by centrifugation at 4000 rpm for 10 min, and the supernatant extracted twice with 20 mL of ethyl acetate (EtOAc). The organic phase was washed with 30 mL of water and subsequently dried with 5 g of anhydrous Na₂SO₄. EtOAc was removed under vacuum at 38 °C and the residue was dissolved in 2.0 mL of EtOAc in a microtube (Eppendorf type-5415C, Hamburg, Germany). The solvent was then evaporated at room temperature under nitrogen gas, and subsequently dipped into liquid nitrogen and lyophilized using a freeze dryer (Edwards Ltd., Crawley, England). The NMR sample preparation and measurements were done according to our previously published protocol.³⁰ For details see⁴⁷.

For separation of metabolites, 15 replicates of *Streptomyces* sp. MBT76-1 culture (750 mL in total) were pooled. After EtOAc extraction, 0.26 g of crude extract was partitioned between methanol and *n*-hexane to remove the lipids. The resolved methanol fraction was subsequently separated by semipreparative reversed-phase HPLC (Phenomenex Luna 5 μ m C18 (2) 100 Å column, 250 \times 10 mm) on an Agilent 1200 series HPLC (Agilent technologies Inc., Santa Clara, CA, USA), eluting with a gradient of ACN in H₂O adjusted with 0.1% TFA from 20% to 60% at a flow rate of 2 mL/min in 40 min. 16 fractions (Fr1—Fr16) were manually collected by peak detection at 254 nm, which were numbered in ascending order of retention time. After rotary evaporation at 42 °C under vacuum, these 16 fractions were further subjected to ¹H NMR profiling and UHPLC-UV-ToF-MS analysis. Qinimycins were

contained in Fr1 (2.1 mg) at retention time 8.12 min.

4.5. UHPLC-UV-ToF-MS analysis

UHPLC-ToF-MS analyses were performed on an UHPLC system (Ultimate 3000, ThermoScientific, Germany) coupled to an ESI-IIQ-TOF spectrometer (micrOTOF-QII, Bruker Daltonics, Germany) in the positive mode.⁴⁸ The chromatographic separation was done using a Kinetex C₁₈ UHPLC 2.6 µm particle size column 150 × 2.0 mm (Phenomenex, USA) at a flow rate of 0.3 mL/min and a column temperature of 30 °C. Samples (3 µL) were eluted using a gradient of solvent A (water) and B (acetonitrile), both with 0.1% formic acid (v/v). The initial percentage of B was 5%, which was linearly increased to 90% in 19.5 min, followed by a 2 min isocratic period and, then re-equilibrated with original conditions in 2 min. Nitrogen was used as drying and nebulizing gas. The gas flow was set at 10.0 L/min at 250 °C and the nebulizer pressure was 2.0 bar. The MS data were acquired over *m/z* range of 100–1000. The capillary voltage was 3.5 kV. For internal calibration, a 10 mM solution of sodium formate (Fluka, Steinheim, Germany) was infused. Formic acid, water and acetonitrile were LCMS grade (Optima, Fisher Scientific, NJ, USA).

4.6. Antimicrobial activity assays

Antimicrobial activity of purified new compounds was determined according to a disc diffusion method as described.^{49, 50} 25 µL of Fr1 (2 mg/mL in methanol) was spotted onto paper discs (6 mm diameter) placed on agar plates containing a soft agar overlay with indicator bacteria. Indicator bacteria were *Bacillus subtilis* 168, *Escherichia coli* ASD19, *Staphylococcus aureus* CECT976, or *Pseudomonas aeruginosa* PAO1. Ampicillin and apramycin were used as positive controls, whereby 5 µL was spotted of a 1 mg/mL solution in miliQ water. The solvent methanol was used as the negative control. After incubation at 37 °C for 18 h, growth inhibition zones (in mm) were recorded as antimicrobial activity.

REFERENCES

- (1) Bérdy, J. J. *Antibiot. (Tokyo)*. **2012**, *65*, 385–395.
- (2) Barka, E. A.; Vatsa, P.; Sanchez, L.; Gaveau-vaillant, N.; Jacquard, C.; Klenk, H.; Clément, C.; Ouhdouch, Y.; van Wezel, Gilles, P. *Microbiol. Mol. Biol. Rev.* **2016**, *80*, 1–43.
- (3) Cooper, M. A.; Shlaes, D. *Nature* **2011**, *472*, 32.
- (4) Kolter, R.; van Wezel, G. P. *Nat. Microbiol.* **2016**, *1*, 15020.
- (5) Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. *Nat. Rev. Drug Discov.* **2007**, *6*, 29–40.
- (6) Bentley, S. D.; Cerdeño-Tárraga, K. F. C. A.-M.; Challis, G. L.; Thomson, N. R.; James, K. D.; Harris, D. E.; Quail, M. A.; Bentley, S. D.; Harper, D.; Bateman, A.; Brown, S.; Collins, M.; Cronin, A.; Fraser, A.; Goble, A.; Hidalgo, J.; Hornsby, T.; Howarth, S.; Larke, L.; Murphy, L.; Oliver, K.; Rabinowitsch, E.; Rutherford, K.; Rutter, S.; Seeger,

- K.; Saunders, D.; Sharp, S.; Squares, R.; Squares, S.; Taylor, K.; Warren, T.; Woodward, J.; Barrell, B. G.; Parkhill, J. *Nature* **2002**, *3*, 141–147.
- (7) Medema, M. H.; Kottmann, R.; Yilmaz, P.; Cummings, M.; Biggins, J. B.; Blin, K.; de Bruijn, I.; Chooi, Y. H.; Claesen, J.; Coates, R. C.; Cruz-Morales, P.; Duddela, S.; Dusterhus, S.; Edwards, D. J.; Fewer, D. P.; Garg, N.; Geiger, C.; Gomez-Escribano, J. P.; Greule, A.; Hadjithomas, M.; Haines, A. S.; Helfrich, E. J. N.; Hillwig, M. L.; Ishida, K.; Jones, A. C.; Jones, C. S.; Jungmann, K.; Kegler, C.; Kim, H. U.; Kötter, P.; Krug, D.; Masschelein, J.; Melnik, A. V.; Mantovani, S. M.; Monroe, E. a; Moore, M.; Moss, N.; Nützmänn, H.-W.; Pan, G.; Pati, A.; Petras, D.; Reen, F. J.; Rosconi, F.; Rui, Z.; Tian, Z.; Tobias, N. J.; Tsunematsu, Y.; Wiemann, P.; Wyckoff, E.; Yan, X.; Yim, G.; Yu, F.; Xie, Y.; Aigle, B.; Apel, A. K.; Balibar, C. J.; Balskus, E. P.; Barona-Gómez, F.; Bechthold, A.; Bode, H. B.; Borriss, R.; Brady, S. F.; Brakhage, A. a; Caffrey, P.; Cheng, Y.-Q.; Clardy, J.; Cox, R. J.; De Mot, R.; Donadio, S.; Donia, M. S.; van der Donk, W. a; Dorrestein, P. C.; Doyle, S.; Driessen, A. J. M.; Ehling-Schulz, M.; Entian, K.-D.; Fischbach, M. a; Gerwick, L.; Gerwick, W. H.; Gross, H.; Gust, B.; Hertweck, C.; Höfte, M.; Jensen, S. E.; Ju, J.; Katz, L.; Kaysser, L.; Klassen, J. L.; Keller, N. P.; Kormanec, J.; Kuipers, O. P.; Kuzuyama, T.; Kyrpides, N. C.; Kwon, H.-J.; Lautru, S.; Lavigne, R.; Lee, C. Y.; Linquan, B.; Liu, X.; Liu, W.; Luzhetskyy, A.; Mahmud, T.; Mast, Y.; Méndez, C.; Metsä-Ketelä, M.; Micklefield, J.; Mitchell, D. a; Moore, B. S.; Moreira, L. M.; Müller, R.; Neilan, B. a; Nett, M.; Nielsen, J.; O’Gara, F.; Oikawa, H.; Osbourn, A.; Osburne, M. S.; Ostash, B.; Payne, S. M.; Pernodet, J.-L.; Petricek, M.; Piel, J.; Ploux, O.; Raaijmakers, J. M.; Salas, J. a; Schmitt, E. K.; Scott, B.; Seipke, R. F.; Shen, B.; Sherman, D. H.; Sivonen, K.; Smanski, M. J.; Sosio, M.; Stegmann, E.; Süßmuth, R. D.; Tahlan, K.; Thomas, C. M.; Tang, Y.; Truman, A. W.; Viaud, M.; Walton, J. D.; Walsh, C. T.; Weber, T.; van Wezel, G. P.; Wilkinson, B.; Willey, J. M.; Wohlleben, W.; Wright, G. D.; Ziemert, N.; Zhang, C.; Zotchev, S. B.; Breitling, R.; Takano, E.; Glöckner, F. O. *Nat. Chem. Biol.* **2015**, *11*, 625–631.
- (8) Fedorova, N. D.; Moktali, V.; Medema, M. H. In *Methods in Molecular Biology*; 2012; Vol. 944, pp. 23–45.
- (9) Zhu, H.; Sandiford, S. K.; van Wezel, G. P. *J. Ind. Microbiol. Biotechnol.* **2014**, *41*, 371–386.
- (10) Rutledge, P. J.; Challis, G. L. *Nat. Rev. Microbiol.* **2015**, *13*, 509–523.
- (11) van Wezel, G. P.; McDowall, K. J. *Nat. Prod. Rep.* **2011**, *28*, 1311–1333.
- (12) Bibb, M. J. *Curr. Opin. Microbiol.* **2005**, *8*, 208–215.
- (13) Abdelmohsen, U. R.; Grkovic, T.; Balasubramanian, S.; Kamel, M. S.; Quinn, R. J.; Hentschel, U. *Biotechnol. Adv.* **2015**, *33*, 798–811.
- (14) Wu, C.; Choi, Y. H.; van Wezel, G. P. *J. Ind. Microbiol. Biotechnol.* **2016**, *43*, 299–312.
- (15) Zhu, H.; Swierstra, J.; Wu, C.; Girard, G.; Choi, Y. H.; van Wamel, W.; Sandiford, S. K.; van Wezel, G. P. *Microbiology* **2014**, *160*, 1714–1725.
- (16) Wu, C.; Zhu, H.; van Wezel, G. P.; Choi, Y. H. *Metabolomics* **2016**, *12*, DOI 10.1007/s11306-016-1025-6.
- (17) Lukashin, A. V.; Borodovsky, M. *Nucleic Acids Res.* **1998**, *26*, 1107–1115.
- (18) Blin, K.; Medema, M. H.; Kazempour, D.; Fischbach, M. A.; Breitling, R.; Takano, E.;

- Weber, T. *Nucleic Acids Res.* **2013**, *41*, 1–9.
- (19) Metsä-Ketelä, M.; Oja, T.; Taguchi, T.; Okamoto, S.; Ichinose, K. *Curr. Opin. Chem. Biol.* **2013**, *17*, 562–570.
- (20) Oja, T.; Galindo, P. S. M.; Taguchi, T.; Manner, S.; Vuorela, P. M.; Ichinose, K.; Metsä-Ketelä, M.; Fallarero, A. *Antimicrob. Agents Chemother.* **2015**, *59*, 6046–6052.
- (21) Okamoto, S.; Taguchi, T.; Ochi, K.; Ichinose, K. *Chem. Biol.* **2009**, *16*, 226–236.
- (22) Ichinose, K.; Ozawa, M.; Itou, K.; Kunieda, K.; Ebizuka, Y. *Microbiology* **2003**, *149*, 1633–1645.
- (23) Ichinose, K.; Bedford, D. J.; Tornus, D.; Bechthold, A.; Bibb, M. J.; Revill, W. P.; Floss, H. G.; Hopwood, D. A. *Chem. Biol.* **1998**, *5*, 647–659.
- (24) Kersten, R. D.; Ziemert, N.; Gonzalez, D. J.; Duggan, B. M.; Nizet, V.; Dorrestein, P. C.; Moore, B. S. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 4407–4416.
- (25) Ramos, J. L.; Martinez-Bueno, M.; Molina-henares, A. J.; Teran, W.; Watanabe, K.; Zhang, X.; Gallegos, M. T.; Brennan, R.; Tobes, R. *Microbiol. Mol. Biol. Rev.* **2005**, *69*, 326–356.
- (26) Novakova, R.; Homerova, D.; Feckova, L.; Kormanec, J. *Microbiology* **2005**, *151*, 2693–2706.
- (27) Novakova, R.; Rehakova, A.; Kutas, P.; Feckova, L.; Kormanec, J. *Microbiology* **2011**, *157*, 1629–1639.
- (28) Novakova, R.; Kutas, P.; Feckova, L.; Kormanec, J. *Microbiology* **2010**, *156*, 2374–2383.
- (29) Bierman, M.; Logan, R.; O'Brien, K.; Seno, E. T.; Rao, R. N.; Schoner, B. E. *Gene* **1992**, *116*, 43–49.
- (30) Kim, H. K.; Choi, Y. H.; Verpoorte, R. *Nat. Protoc.* **2010**, *5*, 536–549.
- (31) Hong, L.; Zhao, Z.; Melanc, C. E.; Zhang, H. *J. Am. Chem. Soc.* **2008**, *130*, 4954–4967.
- (32) Hara, M.; Soga, S.; Shono, K.; Eishima, J.; Mizukami, T. *J. Antibiot. (Tokyo)*. **2001**, *54*, 182–186.
- (33) Taguchi, T.; Okamoto, S.; Hasegawa, K.; Ichinose, K. *ChemBioChem* **2011**, *12*, 2767–2773.
- (34) Hegde, V. R.; King, A. H.; Patel, M. G.; Puar, M. S. *Tetrahedron Lett.* **1987**, *28*, 4485–4488.
- (35) Patel, M.; Hegde, V.; Horan, A.; Barrett, T.; Bishop, R.; King, A.; Marquez, J.; Hare, R.; Gullo, V. *J. Antibiot. (Tokyo)*. **1989**, *42*, 1063–1069.
- (36) Jiang, Z.; Guo, L.; Chen, C.; Liu, S.; Zhang, L.; Dai, S.; He, Q.; You, X.; Hu, X.; Tuo, L.; Jiang, W.; Sun, C. *J. Antibiot. (Tokyo)*. **2015**, *68*, 771–774.
- (37) Taguchi, T.; Yabe, M.; Odaki, H.; Shinozaki, M.; Metsä-Ketelä, M.; Arai, T.; Okamoto, S.; Ichinose, K. *Chem. Biol.* **2013**, *20*, 510–520.
- (38) Tsukamoto, M.; Nakajima, S.; Murooka, K.; Hirayama, M.; Hirano, K.; Yoshida, S.; Kojiri, K.; Suda, H. *J. Antibiot. (Tokyo)*. **2000**, *53*, 26–32.
- (39) Kuniaki, T.; Tomokazu, H.; Masazumi, K.; Yoshikazu, S.; Takashi, O. *J. Antibiot. (Tokyo)*. **2004**, *57*, 291–297.
- (40) Tatsuta, K.; Hosokawa, S. *Sci. Technol. Adv. Mater.* **2006**, *7*, 397–410.
- (41) Taguchi, T.; Itou, K.; Ebizuka, Y.; Malpartida, F.; Hopwood, D. A.; Surti, C. M.; Booker-Milburn, K. I.; Stephenson, G. R.; Ichinose, K. *J. Antibiot. (Tokyo)*. **2000**, *53*,

- 144–152.
- (42) Sambrook, J.; Fritsch, E. F.; Maniatis, T. *Molecular cloning: a laboratory manual*; Cold spring harbor laboratory press: New York, 1989.
- (43) MacNeil, D. J.; Gewain, K. M.; Ruby, C. L.; Dezeny, G.; Gibbons, P. H.; MacNeil, T. *Gene* **1992**, *111*, 61–68.
- (44) Kieser T, Bibb M, Buttner M, Chater K, H. D. *Practical Streptomyces Genetics*; John Innes Foundation: Norwich, United Kingdom, 2000.
- (45) Girard, G.; Willemse, J.; Zhu, H.; Claessen, D.; Bukarasam, K.; Goodfellow, M.; van Wezel, G. P. *Antonie Van Leeuwenhoek* **2014**, *106*, 365–380.
- (46) Colson, S.; Stephan, J.; Hertrich, T.; Saito, A.; van Wezel, G. P.; Titgemeyer, F.; Rigali, S. *J. Mol. Microbiol. Biotechnol.* **2007**, *12*, 60–66.
- (47) Wu, C.; Zacchetti, B.; Ram, A. F. J.; van Wezel, G. P.; Claessen, D.; Choi, Y. H. *Sci. Rep.* **2015**, *5*, 10868.
- (48) Wu, C.; Medema, M. H.; Läkamp, R. M.; Zhang, L.; Dorrestein, P. C.; Choi, Y. H.; van Wezel, G. P. *ACS Chem. Biol.* **2016**, *11*, 478–490.
- (49) Wu, C.; van Wezel, G. P.; Choi, Y. H. *J. Antibiot. (Tokyo)*. **2015**, *68*, 445–452.